Steegmann J L, Granados E, Vázquez L, de la Cámara R, Peñarrubia M J, Fernández-Contreras E, Quiroga J A, Fernández Rañada J M
Servicio de Hematología, Hospital de la Princesa, Madrid.
Sangre (Barc). 1998 Oct;43(5):443-6.
The results of the treatment with lymphoblastoid alpha interferon (IFN-alpha N1) in 10 patients with chronic myeloid leukaemia who had poor response to previous recombinant alpha interferon (rIFN-alpha) are presented. Eight of these patients had not developed anti-alpha 2 interferon antibodies, and 2 had non-neutralising anti-IFN antibodies. Three of the 10 patients received benefit from IFN-alpha N1 treatment. Two of them, with no response to rIFN alpha 2, attained complete haematologic response wit IFN-alpha N1. Cytogenetic responses although minimal, were achieved as well. The third patient, after receiving rIFN-alpha for 3 years with no response, had partial cytogenetic response after 4 months of treatment with IFN-alpha N1. These results suggest that IFN-alpha N1 when used in patients refractory to IFN-alpha N1. These results suggest that IFN-alpha N1 when used in patients refractory to IFN alpha 2 without anti-IFn alpha 2 neutralising antibodies may be useful in a minority of patients, although the frequency of cytogenetic responses is low.
本文报告了10例对先前重组α干扰素（rIFN-α）反应不佳的慢性髓性白血病患者接受淋巴母细胞α干扰素（IFN-α N1）治疗的结果。其中8例患者未产生抗α2干扰素抗体，2例产生了非中和性抗IFN抗体。10例患者中有3例从IFN-α N1治疗中获益。其中2例对rIFN-α2无反应的患者，使用IFN-α N1后获得了完全血液学缓解，细胞遗传学反应虽微小但也得以实现。第3例患者接受rIFN-α治疗3年无反应，使用IFN-α N1治疗4个月后出现了部分细胞遗传学反应。这些结果表明，IFN-α N1用于对IFN-α2难治且无抗IFN-α2中和抗体的患者时，虽细胞遗传学反应频率较低，但可能对少数患者有用。
